North Forty Two & Co. Makes New $393,000 Investment in Stryker Co. (NYSE:SYK)

North Forty Two & Co. purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,092 shares of the medical technology company’s stock, valued at approximately $393,000.

A number of other hedge funds have also bought and sold shares of the stock. VSM Wealth Advisory LLC acquired a new position in Stryker during the 4th quarter valued at approximately $36,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Stryker during the 4th quarter valued at approximately $202,000. Xponance Inc. increased its stake in Stryker by 4.2% during the 4th quarter. Xponance Inc. now owns 59,409 shares of the medical technology company’s stock valued at $21,390,000 after purchasing an additional 2,417 shares in the last quarter. Generali Asset Management SPA SGR acquired a new position in Stryker during the 4th quarter valued at approximately $3,384,000. Finally, Horizon Investments LLC increased its stake in Stryker by 2.4% during the 4th quarter. Horizon Investments LLC now owns 7,752 shares of the medical technology company’s stock valued at $2,791,000 after purchasing an additional 181 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $376.13 on Wednesday. The company’s 50-day moving average price is $383.71 and its 200-day moving average price is $373.82. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market cap of $143.52 billion, a P/E ratio of 48.47, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 EPS. On average, sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SYK. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.